Skip to content
ASCIENDE

The Asciende advantage

Free Mexico shipping from $2,500 MXN

Shipping details

Comparison · Melanocortin analog

Melanotan-1 vs PT-141

These compounds share a catalog class. That grouping makes their declared properties useful to compare, but does not establish experimental or clinical interchangeability.

For in vitro and laboratory research only. Not for human or veterinary use, diagnosis or treatment. These research materials have not been evaluated by COFEPRIS.

What distinguishes these compounds

Melanotan-1 and PT-141 belong to the melanocortin class but have different structures. PT-141 is a cyclic heptapeptide derived structurally from Melanotan-2, with a terminal carboxylic acid in place of an amide; Melanotan-1 is described by its alpha-MSH substitutions.

The entries emphasize different receptor contexts: MC1R in the Melanotan-1 mechanism and MC4R, with reported MC3R involvement, in the PT-141 research description. These summaries do not establish interchangeable effects or a ranking of the materials.

What they are

Melanotan-1: Melanotan-1 is a synthetic analog of alpha-melanocyte-stimulating hormone, with norleucine and D-phenylalanine substitutions described in the literature as determinants of its stability. NDP-alpha-MSH has been studied in in vitro melanocortin receptor binding assays and as a reference for comparing structural variants across subtypes. It has been studied in models of melanogenesis in in vitro studies.

PT-141: PT-141 is a cyclic heptapeptide analog of alpha-MSH, structurally derived from Melanotan-2 by replacing the terminal amide group with a carboxylic acid. In research literature, it binds to melanocortin receptors with a reported preference for MC4R and MC3R. It has been studied in models of central melanocortin signaling in rodent studies.

Mechanisms described in the literature

Melanotan-1: MC1R is a Gs protein-coupled receptor present in melanocytes. Its activation modulates the cyclic AMP pathway and tyrosinase expression in cellular models.

PT-141: MC4R is a Gs protein-coupled receptor expressed in hypothalamic nuclei. Its activation modulates cyclic AMP production in cellular models.

Declared chemical identity, field by field

A dash means that the catalog does not declare that field for the compound. If neither entry declares a field, the row is omitted. A label purity specification of ≥ 99 % is not an analytical result; results must come from the certificate for the relevant batch.

Melanotan-1 vs PT-141: declared technical information
FieldMelanotan-1PT-141
Chemical name[Nle4, D-Phe7]-alpha-MSHAc-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
SequenceAc-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Molecular formulaC78H111N21O19C50H68N14O10
Molecular weight1646.9 Da1025.16 Da
CAS number75921-69-6189691-06-3
FormLyophilized powderLyophilized powder
AppearanceWhite to off-white solidWhite to off-white solid
SolubilitySoluble in sterile water and bacteriostatic waterSoluble in sterile water and bacteriostatic water
Storage−20 °C, protected from light−20 °C, protected from light
Stability after reconstitutionKeep refrigerated at 2–8 °C and use within the period defined by the laboratory protocolKeep refrigerated at 2–8 °C and use within the period defined by the laboratory protocol

Laboratory handling: Melanotan-1

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Laboratory handling: PT-141

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Catalog presentations

Consult each product page for its current presentations, availability, batch documentation and price. This comparison does not freeze commercial information in the research text.

Complete research references

The compendium entries contain the extended definitions, research context and indexed bibliography for each compound. The comparison organizes declared information; it does not replace study-specific interpretation or batch identity evidence.

Sources

  1. Afamelanotide for Erythropoietic Protoporphyria. — N Engl J Med (2015); PMID 26132941; DOI 10.1056/NEJMoa1411481
  2. Afamelanotide for Erythropoietic Protoporphyria. — N Engl J Med (2015); PMID 26132941; DOI 10.1056/NEJMoa1411481
  3. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. — JAMA Dermatol (2015); PMID 25230094; DOI 10.1001/jamadermatol.2014.1875
  4. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. — JAMA Dermatol (2015); PMID 25230094; DOI 10.1001/jamadermatol.2014.1875
  5. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. — Clin Pharmacokinet (2017); PMID 28063031; DOI 10.1007/s40262-016-0501-5
  6. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. — Clin Pharmacokinet (2017); PMID 28063031; DOI 10.1007/s40262-016-0501-5
  7. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. — Int J Dermatol (2017); PMID 28266027; DOI 10.1111/ijd.13585
  8. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. — Int J Dermatol (2017); PMID 28266027; DOI 10.1111/ijd.13585
  9. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. — Obstet Gynecol (2019); PMID 31599840; DOI 10.1097/AOG.0000000000003500
  10. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. — Obstet Gynecol (2019); PMID 31599840; DOI 10.1097/AOG.0000000000003500
  11. Safety Profile of Bremelanotide Across the Clinical Development Program. — J Womens Health (Larchmt) (2022); PMID 35147466; DOI 10.1089/jwh.2021.0191
  12. Safety Profile of Bremelanotide Across the Clinical Development Program. — J Womens Health (Larchmt) (2022); PMID 35147466; DOI 10.1089/jwh.2021.0191
  13. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. — J Sex Med (2006); PMID 16839319; DOI 10.1111/j.1743-6109.2006.00268.x
  14. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. — J Sex Med (2006); PMID 16839319; DOI 10.1111/j.1743-6109.2006.00268.x
  15. Structural insights into ligand recognition and activation of the melanocortin-4 receptor — Cell Res (2021); PMID 34433901; DOI 10.1038/s41422-021-00552-3
  16. Structural insights into ligand recognition and activation of the melanocortin-4 receptor — Cell Res (2021); PMID 34433901; DOI 10.1038/s41422-021-00552-3
  17. Bremelanotide: an overview of preclinical CNS effects on female sexual function — J Sex Med (2007); PMID 17958619; DOI 10.1111/j.1743-6109.2007.00610.x
  18. Bremelanotide: an overview of preclinical CNS effects on female sexual function — J Sex Med (2007); PMID 17958619; DOI 10.1111/j.1743-6109.2007.00610.x
  19. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women — CNS Spectr (2022); PMID 33455598; DOI 10.1017/S109285292100002X
  20. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women — CNS Spectr (2022); PMID 33455598; DOI 10.1017/S109285292100002X
  21. Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. — J Pharm Biomed Anal (2020); PMID 32353679; DOI 10.1016/j.jpba.2020.113276
  22. Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. — J Pharm Biomed Anal (2020); PMID 32353679; DOI 10.1016/j.jpba.2020.113276
  23. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. — Ann N Y Acad Sci (2003); PMID 12851303; DOI 10.1111/j.1749-6632.2003.tb03167.x
  24. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. — Ann N Y Acad Sci (2003); PMID 12851303; DOI 10.1111/j.1749-6632.2003.tb03167.x
  25. PubMed research record — PMID 6777774
  26. PubMed research record — PMID 2992767
  27. PubMed research record — PMID 9671118
  28. EMA: Scenesse composition and pharmaceutical form
Ayuda